ClinicalTrials.gg
CompletedNCT06926660Updated Sep 30, 2026

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

A Phase 2 interventional study of Vicadrostat and Empagliflozin in Chronic Kidney Disease, sponsored by Boehringer Ingelheim. Completed at 157 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Updated Sep 30, 20262 sites added2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
492
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing empagliflozin in Renal Insufficiency, Chronic — 6 open to participants now, 7 under way, 1 of them phase 3. empagliflozin · Renal Insufficiency, Chronic.

Enrollment
5th of 20
492 · median 77
Started
2025
with 2 others
Phase 2
4 of 20
none open now
Registered
16th of 20
by date
Lead sponsor
4 of 20
Boehringer Ingelheim

Among the 20 studies testing empagliflozin in Renal Insufficiency, Chronic, this one is the 5th largest by enrollment, is one of 3 that started in 2025, is one of 4 in phase 2, and was the 16th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

6 of the 20 studies testing empagliflozin in Renal Insufficiency, Chronic are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing empagliflozin in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific type of medication for kidney disease called SGLT2 inhibitor within 1 month before the study or have certain health conditions cannot take part in this study. The purpose of this study is to find out whether a medicine called vicadrostat, used in combination with another medicine called empagliflozin, works in people with chronic kidney disease.

In this study, participants are randomly assigned to one of two groups. Participants have an equal chance of being assigned to either group. In one group, participants take the 2 study medicines, vicadrostat and empagliflozin, every day for 3 months. In the other group, participants take placebo and empagliflozin for the first 1.5 months, and then they take vicadrostat and empagliflozin together for the next 1.5 months. The study medicines are taken orally as tablets. Placebo tablets look like vicadrostat tablets but do not contain any medicine.

Participants are in the study for about 4.5 months. During this time, they visit the study site multiple times. Doctors regularly test kidney function by measuring specific proteins in the blood and urine.

The results are compared between the two groups to see whether there are differences between starting the study medicines at the same time or one after the other. The doctors also regularly check participants' health and take note of any unwanted effects.

03

Conditions studied

  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years old and at least of the legal age of consent in countries where it is greater than 18 years.
  2. Signed and dated written in accordance with ICH-GCP and local legislation prior to admission to the trial.
  3. Male or female participants. Woman of (WOCBP) must be ready and able to use highly effective methods of per International Council on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. For men, birth control is not required during the trial. A list of contraception methods meeting these criteria and instructions on the duration of use is provided in the participant information.
  4. Evidence of Chronic Kidney Disease (CKD) at risk of progression based on two Estimated (eGFR) measurements recorded recently (i.e. within 1 year) and at the time of Visit 1, with each Estimated Glomerular Filtration Rate (eGFR) ≥20 and \<60 mL/min/1.73m2, irrespective of urine albumin creatinine ratio (UACR). The first of these measurements will be In Approval assessed from historical local laboratory results, and the second will be determined from serum creatinine analysed by the central laboratory at Visit 1.
  5. Treatment with a clinically appropriate, stable dose of either Angiotensin-converting enzyme inhibitor (ACEi) or Angiotensin II Receptor Blockers (ARB) (but not both together) for ≥4 weeks before Visit 1, with no planned changes of the therapy for the duration of the trial.

Exclusion criteria

Exclusion Criteria:

  1. Treatment with an SGLT2i within 4 weeks before Visit 2. Treatment with a sodium glucose co transporter 2 inhibitor (SGLT2i) should not be interrupted with the intention of enrolment into the trial.
  2. Treatment with an mineralocorticoid receptor antagonist (MRA), aldosterone synthase inhibitor (ASi), or potassium-sparing diuretic(s) within 14 days prior to Visit 1, or requiring such treatment before randomisation, or planned during the trial, based on the judgment of the investigator. Treatment with an MRA or ASi should not be interrupted with the intention of enrolment into the trial.
  3. Blood potassium of >5.2 mmol/L at Visit 1.
  4. Blood (ALT) or Aspartate aminotransferase (AST) >3x (ULN) at Visit 1.
  5. Known severe hepatic impairment (i.e. class C cirrhosis).
  6. On dialysis, functioning kidney transplant, or scheduled for transplant.
  7. Treated with new therapy for new (or relapse/flare of pre-existing) kidney disease within the last 60 days.
  8. Currently treated with systemic mineralocorticoid replacement therapy (e.g. fludrocortisone).

Further exclusion criteria apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
492 participants (actual)

Study arms

  • Placebo comparator
    Placebo followed by vicadrostat/empagliflozin

    Drug: Vicadrostat · Drug: Empagliflozin · Drug: Placebo matching vicadrostat

  • Experimental
    Vicadrostat/empagliflozin

    Drug: Vicadrostat · Drug: Empagliflozin

Interventions

06

What researchers measure

Primary outcomes

  1. Absolute change in estimated glomerular filtration rate (eGFR) (mL/min/1.73m2) from baseline to Week 14 and week 16

    Time frame: At baseline, up to week 16

Secondary outcomes

  1. Absolute change in estimated glomerular filtration rate (eGFR) (mL/min/1.73m2) from baseline to Week 12

    Time frame: At baseline, up to week 12

  2. Absolute change in systolic blood pressure (SBP) (mmHg) from baseline to Week 12

    Time frame: At baseline, up to week 12

  3. Relative change (ratio) in Urine Albumin Creatinine Ratio (UACR) from baseline to Week 6

    Time frame: At baseline, up to week 6

  4. Absolute change in serum potassium (mmol/L) from baseline to Week 12

    Time frame: At baseline, up to week 12

07

Study locations

157 sites
  • Apogee Clinical Research
    Huntsville, Alabama 35805, United States
  • Orange County Clinical Trials
    Anaheim, California 92801, United States
  • North America Research Institute
    San Dimas, California 91773, United States
  • Valiance Clinical Research-Tarzana-68237
    Tarzana, California 91356, United States
  • Amicis Research Center - Valencia
    Valencia, California 91355, United States
  • Focus Clinical Research
    West Hills, California 91307, United States
  • Clinical Research of Brandon LLC
    Brandon, Florida 33511, United States
  • Hillcrest Medical Research
    DeLand, Florida 32720, United States
  • Encore Medical Research
    Hollywood, Florida 33024, United States
  • Finlay Medical Research Corp
    Miami, Florida 33126, United States
  • Total Research Group, LLC
    Miami, Florida 33126, United States
  • San Marcus Research Clinic, Inc.
    Miami Lakes, Florida 33014, United States
  • West Orange Endocrinology, PA
    Ocoee, Florida 34761, United States
  • Florida Kidney Physicians - Riverview/Brandon
    Riverview, Florida 33578, United States
  • Masters of Clinical Research, Inc
    Augusta, Georgia 30909, United States
  • Boise Kidney and Hypertension, PLLC
    Boise, Idaho 83706, United States
  • Research by Design, LLC
    Chicago, Illinois 60643, United States
  • Nephrology Associates of Northern Illinois and Indiana - Oak Brook
    Hinsdale, Illinois 60521, United States
  • Nephrology Associates of Northern Illinois and Indiana - Fort Wayne
    Fort Wayne, Indiana 46804, United States
  • Kansas Nephrology Research Institute, LLC
    Wichita, Kansas 67214, United States
  • Northwest Louisiana Nephrology
    Shreveport, Louisiana 71101, United States
  • Aa Mrc Llc
    Flint, Michigan 48504, United States
  • Michigan Kidney Consultants
    Pontiac, Michigan 48341, United States
  • Elixia MNA, LLC
    City of Saint Peters, Missouri 63376, United States
  • Healor Primary Care
    Las Vegas, Nevada 89102, United States
  • Endocrine Associates of Long Island
    Smithtown, New York 11787, United States
  • Durham Nephrology Associates
    Durham, North Carolina 27704, United States
  • Lucas Research, Inc.
    Morehead City, North Carolina 28557, United States
  • Brookview Hills Research Associates LLC
    Winston-Salem, North Carolina 27103, United States
  • Heritage Valley Medical Group
    Beaver, Pennsylvania 15009, United States
  • Southeast Renal Research Institute
    Chattanooga, Tennessee 37404, United States
  • Arlington Nephrology
    Arlington, Texas 76015, United States
  • Endocrine Associates
    Houston, Texas 77004, United States
  • Clinical Advancement Center, PLLC
    San Antonio, Texas 78212, United States
  • Javara Inc.-Stephenville-68996
    Stephenville, Texas 76401, United States
  • Utah Kidney Research Institute
    Salt Lake City, Utah 84115, United States
  • Tidewater Physicians Multispecialty Group
    Newport News, Virginia 23606, United States
  • IDIM - Instituto de Diagnostico e Investigaciones Metabolicas
    Buenos Aires, 1012, Argentina
  • CEDIC - Centro de Investigacion Clinica
    CABA, C1060ABN, Argentina
  • Mautalen- Salud e Investigacion
    CABA, C1128AAF, Argentina
  • Instituto Medico Catamarca - IMEC
    Rosario, S2000AJU, Argentina
  • CEMEDIC - Centro de Especialidades Medicas
    Villa Luro, 1407, Argentina
  • John Hunter Hospital
    New Lambton Heights, New South Wales 2305, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Austin Health
    Heidelberg, Victoria 3084, Australia
  • Royal Perth Hospital
    Perth, Western Australia 6000, Australia
  • Hopital Erasme
    Brussels, 1070, Belgium
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Centro de Pesquisa do Hospital Evangelico de Belo Horizonte
    Belo Horizonte, 30220-420, Brazil
  • Chronos Pesquisa Clinica
    Brasília, 72145-450, Brazil
  • Galileo Medical Research Ltda
    Juiz de Fora, 36033-318, Brazil
  • Fundaçao Faculdade Regional de Medicina de Sao Jose do Rio Preto
    São José do Rio Preto, 15090-000, Brazil
  • Cpquali Pesquisa Clinica Ltda
    São Paulo, 01228-000, Brazil
  • Fundacao Oswaldo Ramos (Hospital do Rim)
    São Paulo, 04038-031, Brazil
  • CEPIC - Centro Paulista de Investigacao Clinica e Servicos
    São Paulo, 04266-010, Brazil
  • Centro de Pesquisa Clínica de Nefrologia do ICHC
    São Paulo, 05403-000, Brazil
  • Bluewater Clinical Research
    Sarnia, Ontario N7T 4X3, Canada
  • Heart Health Institute (Scarborough)
    Scarborough Village, Ontario M1B 4Z8, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4G 3E8, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Diex Recherche (Trois-Rivieres)
    Trois-Rivières, Quebec G9A 4P3, Canada
  • Beijing Tsinghua Changgung Hospital
    Beijing, 102218, China
  • West China Hospital, Sichuan University
    Chengdu, 610041, China
  • NanFang Hosptial
    Guangzhou, 510515, China
  • Zhejiang Province People's Hospital
    Hangzhou, 310014, China
  • Center Hospital of Jinan
    Jinan, 250013, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, 330006, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, 210011, China
  • The First People's Hospital of Nanning
    Nanning, 530000, China
  • Ningbo Second Hospital
    Ningbo, 315010, China
  • General Hospital of Ningxia Medical University
    Ningxia, 750004, China
  • Second Hospital Affiliated to Shantou Medical University
    Shantou, 515041, China
  • Shenzhen Second People's Hospital
    Shenzhen, 518035, China
  • First Affiliated Hospital of Xi'an JiaoTong University
    Xi'an, 710061, China
  • Yibin Second People's Hospital
    Yibin, 644099, China
  • DIKa centrum s.r.o.
    Havířov, 73601, Czechia
  • MILAN KVAPIL s.r.o.
    Příbram, 26101, Czechia
  • Nemocnice Slany
    Slaný, 274 01, Czechia
  • HOP Bicêtre
    Le Kremlin-Bicêtre, 94270, France
  • HOP Hôtel-Dieu
    Nantes, 44000, France
  • HOP Civil
    Strasbourg, 67091, France
  • Klinikum Bielefeld
    Bielefeld, 33604, Germany
  • Internistische Gemeinschaftspraxis in Bünde
    Bünde, 32257, Germany
  • Universitätsklinikum Carl Gustav Carus Dresden
    Dresden, 01307, Germany
  • Universitätsklinikum Frankfurt
    Frankfurt, 60590, Germany
  • DaVita Clinical Research Germany GmbH Geilenkirchen
    Geilenkirchen, 52511, Germany
  • Medizinische Hochschule Hannover
    Hanover, 30625, Germany
  • Zentrum Für Nieren Hochdruck und Stoffwechselerkrankungen
    Hanover, 30625, Germany
  • Nephrologische Gemeinschaftspraxis, Hamann/Bacinovic/Jacobsen
    Rotenburg (Wümme), 27356, Germany
  • Robert Bosch Gesellschaft für medizinische Forschung mbH
    Stuttgart, 70376, Germany
  • Azienda Sanitaria Locale 2 Lanciano Vasto Chieti
    Chieti, 66100, Italy
  • Università degli Studi di Perugia
    Perugia, 06132, Italy
  • Istituto di Ricerche Farmacologiche Mario Negri IRCCS
    Ranica (BG), 24020, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Roma, 00168, Italy
  • Kasugai Municipal Hospital
    Aichi, Kasugai, 486-8510, Japan
  • National Hospital Organization Chibahigashi National Hospital
    Chiba, Chiba, 260-8712, Japan
  • Tsuchiura Kyodo General Hospital
    Ibaraki, Tsuchiura, 300-0028, Japan
  • Saiseikai Yokohamashi Nanbu Hospital
    Kanagawa, Yokohama, 234-0054, Japan
  • Osaka General Medical Center
    Osaka, Osaka, 558-8558, Japan

Showing the first 100 of 157 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section 'time frame' are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents -upon signing of a 'Document Sharing Agreement'.For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor'spublication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Aug 2026, 12 months.

Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 12 months is below that.

Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2025
First posted
Apr 14, 2025
StartActual
Jul 18, 2025
Primary completionActual
Aug 14, 2026
CompletionActual
Aug 14, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (1 United States, 1 Brazil)
  • West Orange Endocrinology, PA · Ocoee, United States
  • Fundaçao Faculdade Regional de Medicina de Sao Jose do Rio Preto · São José do Rio Preto, Brazil
Show 2 removed
  • West Orange Endocrinology · Ocoee, United States
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto · São José do Rio Preto, Brazil
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    2 sites added, 2 sites removed
    Show 2 added (1 United States, 1 Brazil)
    • West Orange Endocrinology, PA · Ocoee, United States
    • Fundaçao Faculdade Regional de Medicina de Sao Jose do Rio Preto · São José do Rio Preto, Brazil
    Show 2 removed
    • West Orange Endocrinology · Ocoee, United States
    • Fundação Faculdade Regional de Medicina de São José do Rio Preto · São José do Rio Preto, Brazil

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06926660
Responsible party
Sponsor
First posted
Apr 14, 2025
Start date
Jul 18, 2025
Primary completion
Aug 14, 2026
Completion
Aug 14, 2026
Last update
Sep 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vicadrostat · Empagliflozin

Start the discussion